الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 121 |  |  |
| | | from | 121 | | |
Abstract
Transient tachypnea of the newborn (TTN) is the most frequent cause of early respiratory distress.it occurred because of delayed resorption of the fetal lung fluid, which fills the fetal airways. The inability of the fetal lung to switch from fluid secretion to fluid absorption and an immaturity in the expression of the ENaC may play an important role in the development of TTN.
The aim of the current study was to evaluate the efficacy of inhaled salbutamol, a beta-2 adrenergic agonist, for the treatment of transient tachypnea of the newborn.
This study was conducted as a randomized controlled clinical trial of inhaled salbutamol, inhaled saline on 60 neonates who were admitted immediately or shortly after birth in the neonatal intensive care unit of pediatric department of Menoufia university hospital.
Study group was diagnosed clinically and radiologically. Patients with respiratory distress syndrome, sepsis, pneumonia, meconium aspiration, apparent congenital cardiac diseases, perinatal asphyxia, congenital malformations and non-respiratory disorders (hypocalcaemia, persistent hypoglycemia and polycythemia) were excluded.
Written Informed consents were obtained from parents or care-givers then all the neonates included in the study were subjected to history taking, clinical examination and investigations.
Investigations included: Arterial blood gases, Complete blood count, C–Reactive protein (CRP), Serum glucose and potassium and Chest X-ray.